Loading clinical trials...
Loading clinical trials...
Phase I Part : Confirm the safety of GAIA-102 alone or GAIA-102 with pembrolizumab for advanced / relapse non-small cell lung cancer, and decide recommended dose for Phase II. Phase II Part : Explo...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
GAIA BioMedicine Inc.
NCT05967689 · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
NCT07646288 · VATS, Respiratory Muscles, and more
NCT07489066 · Carcinoma, Non-Small-Cell Lung, and more
NCT07369596 · Non Small Cell Lung Carcinoma NSCLC
NCT07169708 · Non Small Cell Lung Cancer NSCLC
Kyushu University Hospital
Fukuoka, Fukuoka
Kitakyushu Municipal Medical Center
Kitakyushu, Fukuoka
Kurume University Hospital
Kurume, Fukuoka
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions